Gemphire Therapeutics Inc Announces Future Development Plans of Gemcabene for Hypercholesterolemic Patients - Call
Llamada en conferencia Gemphire Therapeutics Inc
Gemphire Therapeutics Inc Conference call will be held on 19-sep-2017. During the earnings conference call's session Gemphire Therapeutics Inc will provide updated information and financial status.
Conference call service enable to conduct an online meeting with several participates at the same time without leaving the room. Earnings call use teleconference platform to conduct an online meeting between the management of a public company, analysts, investors and the media to discuss the financial results during a given reporting period
In order to join the earnings online meeting, contact Gemphire Therapeutics Inc for the information on connecting using web conferencing or bridge number and PIN code
Schedule an online meeting with QCONF conference service and get free conference bridge.
We are a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease. Dyslipidemia is generally characterized by an elevation of low-density lipoprotein cholesterol (LDL-C), or bad cholesterol, triglycerides, or fat in the blood, or both. We are developing our product candidate gemcabene (CI-1027), a novel, once-daily, oral therapy, for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statin therapy. Gemcabene's dual mechanism of action is designed to enhance the clearance of very low-density lipoproteins (VLDLs) in the plasma and inhibit the production of fatty acids and cholesterol in the liver.Leer más Llamada en conferencia